What does CFG Pharma do?

CFG Pharma is registered with the CBE as active in: Vervaardiging van farmaceutische grondstoffen. Private Limited, started on 11 May 2020, 1 establishment.

What is the address of CFG Pharma?

The registered office of CFG Pharma is located at Rue de Liège(CO) 2, 6180 Courcelles.

Is CFG Pharma still active?

Yes. According to the CBE (29 October 2026) CFG Pharma is active, legal situation “Normale toestand”, started on 11 May 2020.

Is CFG Pharma registered on Peppol?

Yes, CFG Pharma is registered on the Peppol network with ID 0208:0746821410.

What is the enterprise number of CFG Pharma?

The enterprise number of CFG Pharma is BE0746821410.

When was CFG Pharma founded?

CFG Pharma was founded on 11 May 2020.

Who are the directors of CFG Pharma?

According to the 2025 annual accounts, the directors of CFG Pharma are: RXW GROUP SA, CRJ FINANCE SRL, NESCH INVEST SRL.

Is CFG Pharma a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 11 May 2020; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did CFG Pharma make in 2025?

CFG Pharma recorded a loss after taxes of € 28,517 in financial year 2025.

What is the revenue of CFG Pharma?

As a small company, CFG Pharma is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -1,097.

CFG Pharma (Private Limited) - Courcelles - BE0746821410

Dossier CFG Pharma, printed on 29 October 2026 from databakkes.be/en/0746821410/cfg-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 4 of the last 4 fiscal years.
Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.

Financials

Financial year 2025

CFG Pharma from Courcelles, company number BE0746821410, closed financial year 2025 with a result of € -28,517 after tax. For that financial year CFG Pharma recorded a gross margin of € -1,097 and equity of € -207,337. Compared with financial year 2024, the result moved from € -31,786 to € -28,517. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 3, 2026.

What it is worth Caution

€ -207,337

▼ € 28,517 vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -28,517

▲ 10 % less loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 99

▼ 98% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -357,337.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 430

▲ 105% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -63,866 Gross margin 2022: € -63,866 First fiscal year in the series	€ -41,639 Gross margin 2023: € -41,639 ▲ € 22,227 vs 2022 (€ -63,866) Favourable step	€ -5,261 Gross margin 2024: € -5,261 ▲ € 36,378 vs 2023 (€ -41,639) Favourable step	€ -1,097 Gross margin 2025: € -1,097 ▲ € 4,165 vs 2024 (€ -5,261) Favourable step	▲ € 4,165
Profit after taxes	€ -74,263 Profit after taxes 2022: € -74,263 First fiscal year in the series	€ -60,787 Profit after taxes 2023: € -60,787 ▲ € 13,477 vs 2022 (€ -74,263) Favourable step	€ -31,786 Profit after taxes 2024: € -31,786 ▲ € 29,000 vs 2023 (€ -60,787) Favourable step	€ -28,517 Profit after taxes 2025: € -28,517 ▲ € 3,269 vs 2024 (€ -31,786) Favourable step	▲ € 3,269
Equity	€ -86,217 Equity 2022: € -86,217 First fiscal year in the series	€ -147,004 Equity 2023: € -147,004 ▼ € 60,787 vs 2022 (€ -86,217) Unfavourable step	€ -178,820 Equity 2024: € -178,820 ▼ € 31,816 vs 2023 (€ -147,004) Unfavourable step	€ -207,337 Equity 2025: € -207,337 ▼ € 28,517 vs 2024 (€ -178,820) Unfavourable step	▼ € 28,517
Total debts	€ 168,766 Total debts 2022: € 168,766 First fiscal year in the series	€ 225,000 Total debts 2023: € 225,000 ▲ 33% vs 2022 (€ 168,766) Unfavourable step	€ 244,395 Total debts 2024: € 244,395 ▲ 9% vs 2023 (€ 225,000) Unfavourable step	€ 258,256 Total debts 2025: € 258,256 ▲ 6% vs 2024 (€ 244,395) Unfavourable step	▲ 6%
Cash	€ 1,730 Cash 2022: € 1,730 First fiscal year in the series	€ 6,758 Cash 2023: € 6,758 ▲ 291% vs 2022 (€ 1,730) Favourable step	€ 4,305 Cash 2024: € 4,305 ▼ 36% vs 2023 (€ 6,758) Unfavourable step	€ 99 Cash 2025: € 99 ▼ 98% vs 2024 (€ 4,305) Unfavourable step	▼ 98%
Retained profit	€ -236,217 Retained profit 2022: € -236,217 First fiscal year in the series	€ -297,004 Retained profit 2023: € -297,004 ▼ € 60,787 vs 2022 (€ -236,217) Unfavourable step	€ -328,820 Retained profit 2024: € -328,820 ▼ € 31,816 vs 2023 (€ -297,004) Unfavourable step	€ -357,337 Retained profit 2025: € -357,337 ▼ € 28,517 vs 2024 (€ -328,820) Unfavourable step	▼ € 28,517
Balance sheet total	€ 82,549 Balance sheet total 2022: € 82,549 First fiscal year in the series	€ 77,996 Balance sheet total 2023: € 77,996 ▼ 6% vs 2022 (€ 82,549) Unchanged	€ 65,574 Balance sheet total 2024: € 65,574 ▼ 16% vs 2023 (€ 77,996) Unchanged	€ 50,919 Balance sheet total 2025: € 50,919 ▼ 22% vs 2024 (€ 65,574) Unchanged	▼ 22%

Key figures of CFG Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to CFG Pharma?

What happened at CFG Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 3, 2026 New annual accounts for financial year 2025: loss of € 28,517. Source: NBB ↗
2023 CRJ FINANCE SRL became a director. NBB
2023 NESCH INVEST SRL became a director. NBB
May 11, 2020 New establishment in Courcelles. KBO
May 11, 2020 Start of the company according to the CBE. KBO
2020 RXW GROUP SA became a director. NBB

In short

From € 74,263 loss in 2022 to € 28,517 loss in 2025.

Original PDFs at the National Bank ↗

Management

RXW Group 100%

The stake of RXW Group comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

CFG Pharma

Behind CFG Pharma are RXW GROUP SA, CRJ FINANCE SRL and NESCH INVEST SRL. The shares are held by RXW Group (100%).

Directors

According to the 2025 annual accounts

RXW GROUP SA

Director · represented by Christiaan Willaert

Also active at: EYTELIA, APR Pharma

since 2020

CRJ FINANCE SRL

Director · represented by Christiaan Willaert

Also active at: RXW Group, Nesch Invest

since 2023

NESCH INVEST SRL

Director · represented by Geert Van Gijseghem

Also active at: MAB Consult Europe, RXW Group, EPM Pharma Invest, PhiDeX Inc., PHIDEX CALN, B+INVEST, B+invest2, Fausto Invest

since 2023

Shareholders

RXW Group

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Rue de Liège(CO) 2

6180 Courcelles

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.

All companies at this address →

PHIDEX CALN same network

€ -88 gross margin · 2025

APR Pharma same network

€ 70,657 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0746.821.410

VAT number

BE 0746.821.410

Registered office

Rue de Liège(CO) 2, 6180 Courcelles

Names & denominations

CFG Pharma

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

11 May 2020

Peppol

Active · Active since 18 Dec 2025

Activities · NACE

Vervaardiging van farmaceutische grondstoffen

Speur- en ontwikkelingswerk op biotechnologisch gebied

Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied

Overige activiteiten van vrije beroepen en andere wetenschappelijke en technische activiteiten, neg

Handelsbemiddeling in de groothandel in meubelen, huishoudelijke artikelen en ijzerwaren

Overige dienstverlenende activiteiten op het gebied van informatie

Overige zakelijke dienstverlening, neg

Overige gespecialiseerde wetenschappelijke en technische activiteiten

View on CBE Public ↗ Annual accounts (NBB) ↗

CFG Pharma

Warning lights

Financials

What happened to CFG Pharma?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions